Cullen Frost Bankers Inc. decreased its position in Allergan PLC. (NYSE:AGN) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,979 shares of the company’s stock after selling 939 shares during the period. Cullen Frost Bankers Inc.’s holdings in Allergan PLC. were worth $10,448,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Enterprise Financial Services Corp raised its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares during the period. Jacobi Capital Management LLC raised its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the period. JNBA Financial Advisors raised its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the period. Webster Bank N. A. raised its position in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares during the period. Finally, Pacific Center for Financial Services raised its position in Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after buying an additional 475 shares during the period. 82.06% of the stock is currently owned by institutional investors.

Shares of Allergan PLC. (NYSE:AGN) opened at 223.86 on Thursday. The stock has a market cap of $74.84 billion, a P/E ratio of 6.82 and a beta of 1.16. The company has a 50 day moving average price of $240.49 and a 200 day moving average price of $238.48. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. Allergan PLC.’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the company posted $3.35 earnings per share. Analysts anticipate that Allergan PLC. will post $16.27 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is 9.95%.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/cullen-frost-bankers-inc-sells-939-shares-of-allergan-plc-agn/1533022.html.

A number of research firms have weighed in on AGN. UBS AG reissued a “buy” rating and set a $275.00 price objective on shares of Allergan PLC. in a research note on Monday, May 15th. Cantor Fitzgerald reissued a “hold” rating on shares of Allergan PLC. in a research note on Tuesday, August 22nd. BidaskClub lowered Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Wells Fargo & Co reissued an “outperform” rating and set a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Finally, Argus reissued a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the stock. Allergan PLC. presently has a consensus rating of “Buy” and a consensus target price of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.